Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Study S0342

PURPOSE: Randomized clinical trials failed to show a survival benefit for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors plus concurrent chemotherapy in patients with metastatic non–small-cell lung cancer (NSCLC), with preclinical data suggesting potential negative interactions....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Herbst, Roy S., Kelly, Karen, Chansky, Kari, Mack, Philip C., Franklin, Wilbur A., Hirsch, Fred R., Atkins, James N., Dakhil, Shaker R., Albain, Kathy S., Kim, Edward S., Redman, Mary, Crowley, John J., Gandara, David R.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2010
Teme:
Original Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3020704/
https://ncbi.nlm.nih.gov/pubmed/20921467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.27.9356
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items